Clinical Trial Results:
            A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathway
    
|     Summary | |
|     EudraCT number | 2010-024394-39 | 
|     Trial protocol | CZ GB BE ES | 
|     Global completion date | 
                                    19 Dec 2011
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    06 Jan 2017
                             | 
|     First version publication date | 
                                    06 Jan 2017
                             | 
|     Other versions | |
|     Summary report(s) | CBEZ235B2201 | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
